Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 47Gynecologic 13Other solid neoplasm 4Thoracic 3Genitourinary 3Gastrointestinal 3CNS 3Breast 3Tumor-Agnostic 1Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Rituximab 1371Cyclophosphamide 1296Vincristine 662Doxorubicin 583Etoposide 525Prednisone 504Cytarabine 481fludarabine 461Methotrexate 441Dexamethasone 411fludarabine phosphate 396Lenalidomide 347Filgrastim 342Bendamustine Hydrochloride 274Radiotherapy 266venetoclax 254ibrutinib 249Peripheral Blood Stem Cell Transplantation 233Melphalan 229obinutuzumab 227Granulocyte Colony-Stimulating Factor 212Bortezomib 204Gemcitabine 201Busulfan 186Whole-Body Irradiation 185Mycophenolic Acid 174Tacrolimus 164Specimen Handling 161Calcium Dobesilate 150Magnetic Resonance Spectroscopy 149

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Trabectedin × Lymphoid × Clear all
NCT03884972 2023-09-25

Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor

M.D. Anderson Cancer Center

Phase 1 Withdrawn
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡